Heart failure etiology affects peripheral vascular endothelial function after cardiac transplantation  by Patel, Ayan R et al.
Heart Failure Etiology Affects Peripheral Vascular
Endothelial Function After Cardiac Transplantation
Ayan R. Patel, MD,* Jeffrey T. Kuvin, MD,* Natesa G. Pandian, MD, FACC,*
John J. Smith, MD, PHD, FACC, James E. Udelson, MD, FACC, Michael E. Mendelsohn, MD, FACC,†
Marvin A. Konstam, MD, FACC, Richard H. Karas, MD, PHD, FACC†
Boston, Massachusetts
OBJECTIVES The goal of this study was to examine the effect of heart failure etiology on peripheral vascular
endothelial function in cardiac transplant recipients.
BACKGROUND Peripheral vascular endothelial dysfunction occurs in patients with heart failure of either
ischemic or nonischemic etiology. The effect of heart failure etiology on peripheral endothelial
function after cardiac transplantation is unknown.
METHODS Using brachial artery ultrasound, endothelium-dependent, flow-mediated dilation (FMD)
was assessed in patients with heart failure with either nonischemic cardiomyopathy (n 5 10)
or ischemic cardiomyopathy (n 5 7), cardiac transplant recipients with prior nonischemic
cardiomyopathy (n 5 10) or prior ischemic cardiomyopathy (n 5 10) and normal controls
(n 5 10).
RESULTS Patients with heart failure with either ischemic cardiomyopathy or nonischemic cardiomy-
opathy had impaired FMD (3.6 6 1.0% and 5.1 6 1.2%, respectively, p 5 NS) compared
with normal subjects (13.9 6 1.3%, p , 0.01 compared with either heart failure group). In
transplant recipients with antecedent nonischemic cardiomyopathy, FMD was markedly
higher than that of heart failure patients with nonischemic cardiomyopathy (13.0 6 2.4%,
p , 0.001) and similar to that of normal subjects (p 5 NS). However, FMD remained
impaired in transplant recipients with prior ischemic cardiomyopathy (5.5 6 1.5%, p 5 0.001
compared with normal, p 5 0.002 vs. transplant recipients with previous nonischemic
cardiomyopathy).
CONCLUSIONS Peripheral vascular endothelial function is normal in cardiac transplant recipients with
antecedent nonischemic cardiomyopathy, but remains impaired in those with prior ischemic
cardiomyopathy. In contrast, endothelial function is uniformly abnormal for patients with
heart failure, regardless of etiology. These findings indicate that cardiac transplantation
corrects peripheral endothelial function for patients without ischemic heart disease, but not in
those with prior atherosclerotic coronary disease. (J Am Coll Cardiol 2001;37:195–200) ©
2001 by the American College of Cardiology
Heart failure is increasing in incidence and prevalence in the
U.S. and is associated with substantial morbidity (1). Im-
paired functional status due to decreased exercise tolerance
contributes significantly to this morbidity. Paradoxically, the
impairment in exercise tolerance correlates poorly with
either central hemodynamic indexes or the degree of left
ventricular dysfunction (2,3). Recent evidence indicates that
peripheral factors play an important role in limiting exercise
tolerance in patients with heart failure (4–8). Since the
vascular endothelium plays a critical role in regulating
vasomotor tone, vascular endothelial dysfunction in patients
with heart failure may result in a diminished vasodilatory
response to exercise and thereby contribute to impaired
exercise tolerance (3,8–11).
Abnormal vascular endothelial function has been de-
scribed in both the coronary and peripheral circulations, and
it occurs in patients with heart failure with either ischemic
or nonischemic cardiomyopathies (9,12–16). Since height-
ened peripheral vasomotor tone contributes to deranged
hemodynamics in heart failure, the ability to reverse endo-
thelial dysfunction has important therapeutic implications.
A variety of interventions have been reported to improve
vascular endothelial function in heart failure, including
angiotensin-converting enzyme (ACE) inhibitor therapy,
physical conditioning, vitamin C, and L-arginine (17–21).
One definitive therapeutic intervention for patients with
severe heart failure is cardiac transplantation. However,
exercise tolerance often remains impaired in cardiac trans-
plant recipients despite normalization of ventricular systolic
function. While endothelial function has been reported to
improve after cardiac transplantation (21,22), the influence
of heart failure etiology on improvement of endothelial
dysfunction has not previously been considered. We hy-
pothesized that the reversibility of vascular endothelial
dysfunction after cardiac transplantation is related to heart
failure etiology. Differences in the reversibility of endothe-
lial dysfunction may, in turn, contribute to variability in the
improvement in functional capacity. As a first step toward
addressing this hypothesis, we undertook this study to
compare the effect of cardiac transplantation on peripheral
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vascular endothelial function in patients with a history or
either ischemic or nonischemic cardiomyopathy.
METHODS
Patients. Study subjects were recruited from the Heart
Failure and Cardiac Transplantation Center at New En-
gland Medical Center. Patients were eligible for this study if
they were clinically stable, were ,70 years old and had
either New York Heart Association (NYHA) class III heart
failure and a left ventricular ejection fraction (LVEF) of
#35% or were cardiac transplant recipients. Transplant
recipients were either outpatients undergoing routine eval-
uation after transplant (n 5 14) or stable patients admitted
for routine annual evaluation after transplant (n 5 6). Heart
failure patients were either outpatients (n 5 16) or inpa-
tients who were clinically stable and at their baseline heart
failure status (n 5 1). No patients were receiving investiga-
tional drugs at the time of the study. Patients who were
clinically unstable or on intravenous vasodilator or inotropic
therapy were excluded. Left ventricular ejection fraction was
determined by radionuclide ventriculography, echocardiog-
raphy, left ventricular cineangiography or gated single-
photon emission computed tomography. All heart failure
patients in the ischemic heart disease group had a history of
prior myocardial infarction, and the presence of coronary
artery disease was confirmed by coronary angiography in six
of seven patients. One patient, in whom coronary angiog-
raphy was not performed, had undergone a thallium myo-
cardial perfusion study that was consistent with ischemic
heart disease. The absence of coronary artery disease in
heart failure patients with nonischemic cardiomyopathy was
confirmed by coronary angiography in 9 of 10 patients. The
patient with nonischemic cardiomyopathy who did not
undergo coronary angiography was subsequently found to
have no evidence of ischemic heart disease by pathologic
examination of the heart after transplantation. Transplant
recipients were clinically stable and had undergone trans-
plant at least three months before enrollment. The etiology
of heart failure in transplant recipients was confirmed by
coronary angiographic findings before transplantation or by
pathologic examination of the explanted heart. Control
subjects were recruited from a group of healthy volunteers
and had no history of cardiac disease or cardiac risk factors.
No subjects who smoked within the past 60 days were
included. All patients enrolled in the study gave written
informed consent. The study was approved by the Human
Investigation Review Committee at the New England
Medical Center.
Vasomotor studies. Using previously validated techniques,
brachial artery imaging was performed with a 7.5 MHz
linear array transducer and ultrasound machine (HDI 5000,
ATL, Bothell, Washington, or SSH-140A/C, Toshiba,
Japan) (23–25). Studies were performed in a quiet room
with the patient lying recumbent. The transducer was
placed 2 cm above the antecubital fossa, and the right
brachial artery was imaged in a longitudinal view. After
optimal longitudinal images were obtained, baseline bra-
chial artery diameter was measured as the distance between
the anterior and posterior intima-blood interfaces. A sphyg-
momanometer cuff (Hokanson, Bellevue, Washington)
placed proximal to the transducer was inflated to
200 mm Hg for 5 min. One minute after cuff deflation,
brachial artery diameter during reactive hyperemia was
obtained. After 10 min, brachial artery measurements were
repeated to establish a second baseline. Sublingual nitro-
glycerin 400 mg was subsequently administered, and repeat
brachial artery diameter measurements were recorded after 3
and 5 min to obtain the maximal arterial diameter. All
images were recorded on VHS videotape. Flow-mediated
dilation (FMD) was calculated as the percent change in
brachial artery diameter from baseline to reactive hyperemia:
[(reactive hyperemia diameter-baseline diameter)/baseline
diameter] 3 100. Brachial artery dilation after nitroglycerin
was calculated as the percent change in brachial artery
diameter from prenitroglycerin baseline to after administra-
tion of nitroglycerin. Endothelium-dependent vasodilation
was assessed by measuring FMD during reactive hyperemia.
Endothelium-independent vasodilation was measured as
change in arterial diameter after nitroglycerin. Two inde-
pendent observers who were blinded to the patient’s clinical
data interpreted the studies.
Reproducibility. Analysis of reproducibility of brachial
artery studies in our laboratory has demonstrated a mean
difference in FMD of 1.9% for intraobserver variability and
2.8% for interobserver variability.
Statistical analysis. Comparisons of brachial artery reac-
tivity between ischemic cardiomyopathy, nonischemic car-
diomyopathy and normal control subjects were made using
one-way analysis of variance, followed by Student-
Newman-Keuls tests for multiple pairwise comparisons. In
both the heart failure and posttransplant populations, base-
line characteristics of patients with a history of ischemic
cardiomyopathy and those with a history of nonischemic
cardiomyopathy were compared using a Student t-test for
continuous variables. Noncontinuous variables were com-
pared using Fisher exact test. Data are presented as mean 6
SEM, and differences were considered to be significant at a
p value ,0.05.
RESULTS
Baseline characteristics. Peripheral vascular endothelial
function was assessed in 17 patients with NYHA class III
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
FMD 5 flow-mediated dilatation
LVEF 5 left ventricular ejection fraction
NYHA 5 New York Heart Association
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heart failure, 20 heart transplant recipients and 10 normal
controls.
Patients with heart failure. Baseline characteristics of the
patients with heart failure are shown in Table 1. The heart
failure group included 7 patients with ischemic cardiomy-
opathy and 10 patients with nonischemic cardiomyopathy,
with a mean LVEF of 19 6 1% and 17 6 1%, respectively
(p 5 NS). The heart failure population included two
postmenopausal women, both of whom had nonischemic
cardiomyopathy and were not receiving hormone replace-
ment therapy.
There were no significant differences between ischemic
and nonischemic cardiomyopathy patients in baseline char-
acteristics, including age, prevalence of diabetes and hyper-
tension, history of prior smoking, total cholesterol levels,
low-density lipoprotein cholesterol levels, mean LVEF or
treatment with ACE inhibitors. As expected, there was a
trend towards a higher frequency of lipid-lowering therapy
for patients with ischemic heart disease (p 5 0.06). In
addition, there was a trend towards lower high-density
lipoprotein cholesterol levels among patients with ischemic
cardiomyopathy (p 5 0.06).
Transplant recipients. Baseline characteristics for cardiac
transplant recipients are shown in Table 2. The cardiac
transplant group comprised 10 patients with a history of
ischemic cardiomyopathy and 10 patients with a history of
nonischemic cardiomyopathy. There were no women in the
ischemic cardiomyopathy transplant group, and there were
two postmenopausal women in the nonischemic group, one
of whom was receiving transdermal estrogen replacement.
None of the transplant recipients were current smokers.
Cardiac transplant recipients were studied at an average of
33 6 8 months after transplant. The mean pretransplant
LVEF for this group was 19.8 6 2.6% for patients with a
history of ischemic cardiomyopathy and 15.7 6 1.7% for
patients with a history of nonischemic cardiomyopathy (p 5
NS). No patients received lymphocytolytic therapy as in-
duction treatment. Five patients with prior ischemic cardio-
myopathy and four patients with prior nonischemic cardio-
myopathy had a history of rejection requiring therapy
(p 5 NS), but none of these patients had evidence of
rejection at the time of the study. Six patients (60%) with a
history of ischemic cardiomyopathy and four patients (40%)
with a history of nonischemic cardiomyopathy had partici-
pated in a rehabilitation program after undergoing cardiac
transplant (p 5 NS). Five patients (50%) with a history of
ischemic cardiomyopathy and five patients (50%) with prior
nonischemic cardiomyopathy were receiving prednisone
therapy at the time of the study (p 5 NS). One patient
(10%) with prior ischemic cardiomyopathy and two patients
(20%) with prior nonischemic cardiomyopathy were treated
with mycophenolate (p 5 NS). Seven patients (70%) with a
history of ischemic cardiomyopathy and seven patients
(70%) with prior nonischemic cardiomyopathy were treated
with azathioprine (p 5 NS). Among heart transplant
recipients, there were no significant differences in baseline
characteristics between ischemic cardiomyopathy and non-
ischemic cardiomyopathy patients.
Vasomotor studies. Brachial artery diameters at baseline,
during reactive hyperemia, prior to nitroglycerin and after
administration of nitroglycerin are shown in Table 3.
Endothelium-dependent, flow-mediated vasodilation in pa-
tients with heart failure, transplant recipients and normal
controls is shown in Figure 1. Patients with heart failure due to
nonischemic cardiomyopathy or ischemic cardiomyopathy had
markedly impaired FMD (3.6 6 1.0% and 5.1 6 1.2%,
respectively) compared with normal controls (13.9 6 1.3%,





Age (yrs) 56 6 3 54 6 2
Duration of heart failure (yrs) 4.2 6 1.3 5.3 6 2.0
LVEF (%) 19 6 2 17 6 1
Hypertension (#) 1 1
Diabetes (#) 2 0
History of smoking (#) 5 5
Total cholesterol (mg/dl) 151 6 8 166 6 13
HDL (mg/dl) 32 6 2 41 6 4
LDL (mg/dl) 89 6 5 107 6 11
Triglycerides (mg/dl) 139 6 42 138 6 19
ACE-inhibitor use (#) 6 10
Mean captopril equivalent dose (mg/day) 156 6 15 135 6 31
ARB use (#) 1† 0
Lipid-lowering therapy (#) 5 2
*p 5 NS for all comparisons; †treated with losartan 50 mg daily.
ACE 5 angiotensin-converting enzyme; ARB 5 angiotensin-receptor blocker;
HDL 5 high-density lipoprotein cholesterol; LDL 5 low-density lipoprotein
cholesterol; LVEF 5 left ventricular ejection fraction.





Age (yrs) 54 6 3 50 6 4
Time since transplant (months) 30 6 9 38 6 15
Duration of heart failure before
transplant (yrs)
2.8 6 0.8 3.6 6 0.3
LVEF (%) 53 6 3 55 6 2
Hypertension 8 7
Systolic blood pressure (mm Hg) 136 6 6 131 6 3
Diastolic blood pressure (mm Hg) 85 6 4 86 6 3
Diabetes (#) 2 2
History of smoking (#) 7 5
Total cholesterol (mg/dl) 201 6 17 194 6 13
HDL (mg/dl) 43 6 3 43 6 3
LDL (mg/dl) 114 6 13 97 6 11
Cyclosporine therapy (#) 10 9
Cyclosporine level 335 6 24 361 6 55
Beta-blockers (#) 1 2
Calcium-channel blockers (#) 7 6
Diuretics (#) 5 3
Alpha-blockers (#) 0 1
ACE inhibitors (#) 1 1
ARB (#) 0 1
Lipid-lowering therapy (#) 7 5
*p 5 NS for all comparisons.
ACE 5 angiotensin-converting enzyme; ARB 5 angiotensin receptor blocker;
HDL 5 high-density lipoprotein cholesterol; LDL 5 low-density lipoprotein
cholesterol; LVEF 5 left ventricular ejection fraction.
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p , 0.01 for normal subjects vs. either nonischemic or
ischemic cardiomyopathy subjects, p 5 NS for subjects with
nonischemic cardiomyopathy vs. subjects with ischemic
cardiomyopathy).
In the transplant recipient group, FMD was normal in
patients with a history of nonischemic cardiomyopathy
(13.0 6 2.4%, p 5 NS vs. normal controls). Furthermore,
FMD in transplant recipients with previous nonischemic
cardiomyopathy was significantly higher than that of heart
failure patients with nonischemic cardiomyopathy (p 5
0.001). In contrast, endothelial function was severely im-
paired in transplant recipients with a history of ischemic
cardiomyopathy (5.5 6 1.5%, p 5 0.001 compared with
normal controls, p 5 0.002 vs. transplant recipients with
prior nonischemic cardiomyopathy).
Compared with normal controls, endothelium-
independent vasodilation in response to nitroglycerin was
preserved in all patient groups, regardless of heart failure
etiology (Fig. 2). There were no significant differences
among patient groups in endothelium-independent vasodi-
lation (p 5 0.24 for patients with heart failure; p 5 0.14 for
transplant recipients).
DISCUSSION
This study demonstrates that: 1) peripheral vascular endo-
thelial function is similarly impaired in patients with heart
failure of either ischemic or nonischemic etiology and 2)
peripheral vascular endothelial function is normal after
cardiac transplantation in patients with prior nonischemic
cardiomyopathy, but not in those with prior ischemic
cardiomyopathy. It is interesting to note that the presence of
concomitant heart failure and coronary artery disease did
not lead to worsened endothelial dysfunction for patients
with ischemic cardiomyopathy compared with patients who
had nonischemic cardiomyopathy. While previous studies
have reported improvement in peripheral vascular endothe-
lial function in patients with heart failure after cardiac
transplantation, the influence of heart failure etiology on the
improvement of endothelial function has not been previ-
ously assessed (21,22). The persistence of endothelial
dysfunction for patients with ischemic heart disease under-
scores the systemic pathophysiology of the atherosclerotic
process. The absence of endothelial dysfunction after trans-
plantation in patients with nonischemic cardiomyopathy
suggests that endothelial dysfunction in patients with heart
Figure 1. Endothelium-dependent vasodilation. The percent change in
brachial artery diameter during reactive hyperemia in heart failure patients
(open bars) and transplant recipients (closed bars) compared with normal
controls (hatched bars) is shown. Compared with controls, flow-mediated
dilation (FMD) was significantly decreased in heart failure patients with
either ischemic cardiomyopathy or nonischemic cardiomyopathy. Flow-
mediated dilation was also impaired in transplant recipients with a history
of ischemic cardiomyopathy. In contrast, FMD in transplant recipients
with a history of nonischemic cardiomyopathy was significantly higher than
that of heart failure patients with nonischemic cardiomyopathy or trans-
plant recipients with a history of ischemic heart disease. *p , 0.05
compared with normal control.
Figure 2. Endothelium-independent vasodilation. The percent change in
brachial artery diameter after administration of nitroglycerin in heart failure
patients (open bars) and transplant recipients (closed bars) compared with
normal controls (hatched bars) is shown. There were no significant
differences between groups.













Baseline 4.06 6 0.15 4.29 6 0.19 4.37 6 0.15 4.04 6 0.19 3.68 6 0.18
Hyperemia 4.24 6 0.14 4.44 6 0.21 4.58 6 0.17 4.51 6 0.17 4.14 6 0.20
Change in diameter (baseline to
hyperemia)
0.17 6 0.06* 0.15 6 0.04* 0.24 6 0.07* 0.51 6 0.08 0.50 6 0.05
Baseline 2† 4.18 6 0.13 4.23 6 0.20 4.45 6 0.15 4.10 6 0.23 3.70 6 0.19
After nitroglycerin 4.75 6 0.07 4.85 6 0.22 4.96 6 0.12 4.77 6 0.22 4.42 6 0.23
Change in diameter (baseline 2 to
nitroglycerin)
0.54 6 0.8 0.61 6 0.08 0.51 6 0.09 0.64 6 0.09 0.66 6 0.17
*p , 0.05 compared with control; †baseline 2 5 prenitroglycerin baseline.
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failure of nonischemic etiology is caused by dynamic factors
related to the physiologic derangements that accompany
severe heart failure.
Mechanisms for endothelial dysfunction in heart failure.
While the precise mechanisms that cause abnormal vaso-
motor function in heart failure have not been elucidated,
decreased bioavailability of nitric oxide is likely to play an
important role in impaired endothelium-dependent vasodi-
lation. High tissue and circulating levels of angiotensin II
for patients with heart failure may promote superoxide
radical formation, resulting in increased degradation of
nitric oxide (26). Improvement of endothelial function after
cardiac transplantation in nonischemic cardiomyopathy pa-
tients might, therefore, be related to decreased activation of
the renin-angiotensin system. However, for patients with a
history of ischemic heart disease, the presence of systemic
atherosclerosis may lead to persistent endothelial dysfunc-
tion in spite of improved hemodynamic and neurohormonal
conditions.
Clinical implications. Peripheral vascular endothelial
function may have important implications for functional
capacity in patients with heart failure, as well as in trans-
plant recipients. Exercise capacity in both heart
failure patients and transplant recipients correlates poorly
with LVEF and resting central hemodynamic abnormali-
ties, and there is evidence that peripheral factors affect
functional capacity in these patients (2,3,7,8). For example,
Kraemer et al. (8) observed a correlation between forearm
blood flow during reactive hyperemia and peak oxygen
uptake during exercise in patients with heart failure. In
addition, Andreassen et al. (6) recently observed that
impaired endothelium-dependent vasodilation of the pe-
ripheral microcirculation was associated with diminished
exercise capacity in cardiac transplant recipients. Further-
more, improvements in vasomotor function may enhance
functional status. Mancini et al. (4) found a correlation
between captopril-induced augmentation of peak exercise
skeletal muscle blood flow and improved maximal oxygen
consumption in heart failure patients. Similarly, Nakamura
et al. (5) observed a correlation between improved
endothelium-dependent vasodilation and peak oxygen con-
sumption in patients with valvular disease and heart failure
who underwent valve surgery. Based on these previous
studies, the finding that endothelial function improves in
nonischemic but not in ischemic cardiomyopathy patients
after cardiac transplantation may have direct implications
for functional recovery after transplantation in this patient
population.
Other potential risk factors for endothelial dysfunction
in transplant recipients. All transplant recipients except
one received treatment with cyclosporine, and one patient
received tacrolimus. Patients with prior ischemic cardiomy-
opathy had similar cyclosporine levels compared with those
with prior nonischemic cardiomyopathy, and cyclosporine-
induced hypertension was highly prevalent in both trans-
plant groups. Of note, although hypertension is associated
with impaired endothelial function (27–29), patients with
nonischemic cardiomyopathy still manifested normal endo-
thelial function after transplantation. In addition, transplant
recipients in both the ischemic and nonischemic groups had
similar profiles with regard to other factors known to affect
endothelial function, including lipid levels, diabetes, history
of smoking and use of lipid-lowering therapy.
Study limitations. The lack of longitudinal patient
follow-up is a limitation of this study. However, the pretrans-
plant characteristics of the transplant recipients with a history
of nonischemic cardiomyopathy were similar to those of the
corresponding heart failure group. Thus, there were no iden-
tifiable clinical differences between the nonischemic transplant
recipient group and the nonischemic cardiomyopathy group
that could explain the observed differences in endothelial
function. In addition, the pretransplant characteristics of trans-
plant recipients with a history of ischemic heart disease were
similar to those of the patients with heart failure who had
ischemic cardiomyopathy.
Conclusions. This study confirms the observation that
peripheral vascular endothelial function is abnormal in
patients with heart failure, regardless of etiology, and
demonstrates that peripheral vascular endothelial function is
normal after cardiac transplantation in patients with nonisch-
emic cardiomyopathy, but not in those with ischemic
cardiomyopathy. Thus, the reversibility of peripheral vascu-
lar endothelial dysfunction in heart failure is linked to the
presence or absence of coronary atherosclerotic disease. The
persistent peripheral vascular endothelial dysfunction in
transplant recipients with a history of coronary atheroscle-
rosis is presumably related to the presence of systemic
atherosclerosis. In contrast, endothelial dysfunction in pa-
tients with nonischemic cardiomyopathy is likely a conse-
quence of hemodynamic abnormalities and is reversible after
cardiac transplantation. Determination of the implications
of these observations as they relate to recovery of functional
status in heart failure patients undergoing cardiac transplan-
tation must await future investigation.
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